The scientific committee
overseeing Britain’s coronavirus vaccination programme on Friday recommended
that under-40s are offered an alternative to the Oxford-AstraZeneca COVID jab.

The
Joint Committee on Vaccination and Immunisation (JCVI) said it was taking the
“precautionary approach” for adults aged 30-39, after assessment of
blood clot risks.

Professor
Wei Shen Lim of the JCVI advisory committee said that those aged 30-39 will be
“preferentially offered an alternative to the AstraZeneca vaccine”.

Also Read | Saudi Arabia to allow only vaccinated employees back to workplace

This
will happen as long as an alternative is available and does not create a
substantial delay in vaccination, and as long as the UK keeps its virus
situation under control, he added.

Lim
said the aim was to “further increase vaccine confidence” as
under-40s are due to be vaccinated soon, by showing that the government is
putting a “high priority on safety”.

The
UK — which launched its mass vaccination drive in December last year with the
Pfizer-BioNTech shot — is still on track to give all adults a first vaccine
dose by the end of July, Lim said.

Also Read | Study finds formation of rare brain blood clots after single AstraZeneca dose

He
added that the success of the vaccine rollout means that “a future wave of
infection is likely to be smaller than anticipated”.

June
Raine, who heads the UK’s Medicines and Healthcare products Regulatory Agency,
said it was not changing its advice on the AstraZeneca vaccine as side effects
were “extremely rare”.

From
more than 28 million first doses of the vaccine administered in the UK by April
28, there were 242 cases reported of clots combined with low blood platelet
levels, or 10.5 per million, she said.

Also Read | How are nations across the globe faring against COVID-19 pandemic

These
clots occurred in 141 women and 100 men aged from 18 to 93, and the overall
case death rate was 20 percent, with 49 deaths.

Six
cases have been reported after a second dose of the vaccine.

Raine
said this meant that the benefits of the AstraZeneca vaccine still outweigh the
risks of coronavirus for the vast majority of people.

For
younger people, this ratio is “more fully balanced,” she said,
however.

Nearly
128,000 people have died from the virus in the UK, the highest figure in
Europe.

The
UK has now administered nearly 35 million first doses of vaccine and more than
16 million second doses.

Also Read | Pfizer/BioNTech COVID vaccine shows 95% efficacy in largest, real-world study

A
government spokesman said it would follow the advice, adding: “The
Oxford-AstraZeneca vaccine is safe, effective and has already saved thousands of
lives in the UK and around the world…

“More
than 50 million vaccines overall have already been administered, and our
current vaccine supply and rate of infection means we are able to take this
precautionary step while remaining on track to achieve our target of offering a
vaccine to all adults by the end of July.”